SLC2A1 and Obesity: These data highlight a direct therapeutic role for hepatocyte NAMPT activation downstream of generalized fasting or hepatocyte GLUT inhibition, which can be utilized against obesity, aging, neurodegenerative, and other fasting-labile diseases.